{"id":"disitamab-vedotin-injection-18-weeks","safety":{"commonSideEffects":[{"rate":"34%","effect":"Neutropenia"},{"rate":"24%","effect":"Thrombocytopenia"},{"rate":"21%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Disitamab vedotin targets CD6, a protein involved in the activation and proliferation of T cells, which play a key role in the immune response.","oneSentence":"Anti-CD6 monoclonal antibody","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:10:57.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06178159","phase":"PHASE2","title":"DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-11-28","conditions":"Breast Cancer","enrollment":40},{"nctId":"NCT06227117","phase":"PHASE2","title":"Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2023-07-27","conditions":"Breast Cancer","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DV,RC48-ADC"],"phase":"phase_2","status":"active","brandName":"Disitamab Vedotin Injection （18 weeks）","genericName":"Disitamab Vedotin Injection （18 weeks）","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-CD6 monoclonal antibody Used for Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}